This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Tremblay G, et al. Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in France. European Journal of Health Economics : 22 Jan 2020. Available from: URL: https://doi.org/10.1007/s10198-019-01149-9
About this article
Cite this article
Midostaurin cost effective for FLT3-mutated AML. PharmacoEcon Outcomes News 846, 18 (2020). https://doi.org/10.1007/s40274-020-6557-3